Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $86.00 short call and a strike $91.00 long call offers a potential 14.16% return on risk over the next 20 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $86.00 by expiration. The full premium credit of $0.62 would be kept by the premium seller. The risk of $4.38 would be incurred if the stock rose above the $91.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 46.69 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Elanco Announces Global Agreement with Ab E Discovery for New Technology
Thu, 25 Jan 2018 23:27:00 +0000
The potential innovation furthers Elanco's commitment to antibiotic stewardship and offering alternatives to unmet needs. GREENFIELD, Ind., Jan. 25, 2018 /PRNewswire/ — Elanco Animal Health, a division of Eli Lilly and Company (LLY), is pleased to announce a new global in-licensing agreement with Ab E Discovery to further develop and bring to market an egg antibody focused on supporting gut health, and thereby the growth and welfare, of poultry. Adding egg proteins to the diets of young birds passes on antibodies to improve gut health.
See what the IHS Markit Score report has to say about Eli Lilly And Co.
Thu, 25 Jan 2018 13:01:01 +0000
Eli Lilly And Co NYSE:LLY
Celgene on the Street: Analysts Recommendations in January
Thu, 25 Jan 2018 12:33:27 +0000
Celgene to Acquire Juno Therapeutics: A Deeper Read
Novartis Receives 2 Breakthrough Therapy Designations in January
Thu, 25 Jan 2018 12:31:37 +0000
How Novartis Is Positioned for 2018
Latest Alzheimer's Flop Raises Doubts About ‘Amyloid Hypothesis'
Wed, 24 Jan 2018 22:00:00 +0000
Eli Lilly's experimental Alzheimer’s drug solanezumab has once again produced disappointing results from a clinical trial. Is it time to rethink the notion that amyloid deposits in the brain drive this disease?
Also on Market Tamer…
Follow Us on Facebook